Rigel Pharmaceuticals has suffered over the past year, but it seems this update may be the catalyst it has been looking for.
Rigel Pharmaceuticals watched its shares make a handy uptick on Monday after the FDA approved its New Drug Application for the use of Tavalisse in patients with chronic or persistent immune...
Rigel Pharmaceuticals shares saw a solid gain to kick off the week after the company gave an update on one of its clinical programs.
Some companies are hitting lows and creating huge shareholder losses while the market is just below all-time highs but still struggling. These are the same companies holding back the market and...
Rigel Pharmaceuticals shares slid on Thursday after the company announced results from its late-stage clinical trial.
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in November and December.
Shares of Rigel Pharmaceuticals skyrocketed early on Tuesday after the company reported incredibly positive results from its late-stage blood platelet clinical trial.
Investors in the biotech and biohealth space generally are taking on much more risk than in the likes of most Dow and S&P 500 stocks. That means they will demand more potential upside for that...
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include EMC, MetLife, Pandora Media, Whiting Petroleum, Yelp, Mosaic and Oasis Petroleum.
The top analyst upgrades, downgrades and initiations seen on Monday morning include Advanced Micro Devices, Agios Pharmaceuticals, Baidu, Diamond Offshore Drilling, LyondellBasell and Occidental...
Stocks were directionless on Monday, despite weak economic data from China over the weekend. Investors have proven over and over that they are still looking for opportunities and hidden gems, and so...
Rigel Pharmaceuticals and Bristol-Myers Squibb announced Monday morning that they have entered into a collaboration agreement.
This past week we scoured our Wall Street coverage looking for analysts stock picks that have huge upside targets, and we were not disappointed. We found five stocks from four different firms.
Source: ThinkstockStocks hit new highs this past week, only to sell off handily. Investors want gains, but they remain wary. 24/7 Wall St. reviews dozens of analyst research reports from Wall Street...
Source: ThinkstockThe biotech meltdown that started in late February was an indiscriminate killer. The top mega-cap sector leaders were shot down in flames along with small cap names that have yet to...